4.8 Article

Metastatic cancers promote cachexia through ZIP14 upregulation in skeletal muscle

Journal

NATURE MEDICINE
Volume 24, Issue 6, Pages 770-+

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/s41591-018-0054-2

Keywords

-

Funding

  1. NASA Ames Research Center [NNA06CB93G]
  2. National Institutes of Health (NIH) [P50CA127297, U01CA210240, 5R50CA211462]
  3. National Cancer Institute [R00CA172697]
  4. Institutional start-up funds from CUIMC
  5. Herbert Irving Comprehensive Cancer Center's Cancer Center Support Grant-Inter-Programmatic Pilot Project [5P30CA013696-43]
  6. [DK080706]

Ask authors/readers for more resources

Patients with metastatic cancer experience a severe loss of skeletal muscle mass and function known as cachexia. Cachexia is associated with poor prognosis and accelerated death in patients with cancer, yet its underlying mechanisms remain poorly understood. Here, we identify the metal-ion transporter ZRT-and IRT-like protein 14 (ZIP14) as a critical mediator of cancerinduced cachexia. ZIP14 is upregulated in cachectic muscles of mice and in patients with metastatic cancer and can be induced by TNF-alpha and TGF-beta cytokines. Strikingly, germline ablation or muscle-specific depletion of Zip14 markedly reduces muscle atrophy in metastatic cancer models. We find that ZIP14-mediated zinc uptake in muscle progenitor cells represses the expression of MyoD and Mef2c and blocks muscle-cell differentiation. Importantly, ZIP14-mediated zinc accumulation in differentiated muscle cells induces myosin heavy chain loss. These results highlight a previously unrecognized role for altered zinc homeostasis in metastatic cancer-induced muscle wasting and implicate ZIP14 as a therapeutic target for its treatment.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available